A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

ClinicalTrials.gov ID: NCT04859777

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04859777. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: * Part A: MPT-0118 dose-escalation * Part B: MPT-0118 dose-escalation in combination with pembrolizumab * Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab

Study identification

NCT ID: NCT04859777
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Monopteros Therapeutics Inc.; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Interventions

MPT-0118 Drug
MPT-0118 + pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 13, 2021 (Actual)
Primary completion: Mar 2023 (Estimated)
Completion: Mar 2023 (Estimated)
Last update posted: Sep 16, 2021

2021 – 2023

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
St. John's Cancer Center	Santa Monica	California	90404	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Columbia University	New York	New York	10032	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology	San Antonio	Texas	78229	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04859777, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 16, 2021 · Synced Nov 13, 2026